Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review

International Journal of Antimicrobial Agents

Volumn 53, Issue 1, 2019, Pages 16-21

  Kakasis, Athanasios ^a   Panitsa, Gerasimia ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Antibiotic resistance; Antimicrobial resistance; Bacteriophage; Bacteriophage therapy; Phage; Phage therapy

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE; BIOLOGY; DRUG EFFECT; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; ANIMAL; BACTERIUM; VIROLOGY;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; HUMANS; PHAGE THERAPY;

EID: 85056995775     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.09.004     Document Type: Review

References (82)

1. WHO | WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health [Internet]. WHO. [cited 2018 Apr 15]. Available from: http://www.who.int/mediacentre/news/releases/2014/amr-report/en/.
2. Antibiotic/Antimicrobial Resistance | CDC [Internet] 2018 [cited 2018 Apr 15]. Available from: https://www.cdc.gov/drugresistance/index.html.
3. Summary of the latest data on antibiotic resistance in the European Union [Internet]. European Centre for Disease Prevention and Control. 2017 [cited 2018 Apr 15]. Available from: http://ecdc.europa.eu/en/publications-data/summary-latest-data-antibiotic-resistance-european-union.
4. Projan, S.J., Why is big pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol 6:5 (2003), 427–430.
5. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V.A., et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16:2 (2016), 239–251.
6. Keen, E.C., A century of phage research: bacteriophages and the shaping of modern biology. BioEssays News Rev Mol Cell Dev Biol 37:1 (2015), 6–9.
7. Richard, Sharp, Bacteriophages: biology and history. J Chem Technol Biotechnol 76:7 (2001), 667–672.
8. Kutter, E., Sulakvelidze, A., Bacteriophages: Biology and Applications. 2004, CRC Press, 527.
9. Cisek, A.A., Dąbrowska, I., Gregorczyk, K.P., Wyżewski, Z., Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol 74:2 (2017), 277–283.
10. Lin, D.M., Koskella, B., Lin, H.C., Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8:3 (2017), 162–173.
11. Clark, J.R., Bacteriophage therapy: history and future prospects. Future Virol 10:4 (2015), 449–461.
12. An investigation on the nature of ultra-microscopic viruses by Twort FW, L.R.C.P. Lond., M.R.C.S. (From the Laboratories of the Brown Institution, London). Bacteriophage 1:3 (2011), 127–129.
13. D'Herelle, F., On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. Res Microbiol 158:7 (2007), 553–554.
14. Abedon, S.T., Kuhl, S.J., Blasdel, B.G., Kutter, E.M., Phage treatment of human infections. Bacteriophage 1:2 (2011), 66–85.
15. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:1 (2010), 69–86.
16. Chanishvili, N., Phage therapy–history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 83 (2012), 3–40.
17. Chanishvili, N., Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and post-Soviet experiences. Curr Drug Deliv 13:3 (2016), 309–323.
18. Salmond, G.P.C., Fineran, P.C., A century of the phage: past, present and future. Nat Rev Microbiol 13:12 (2015), 777–786.
19. Gill, J.J., Hyman, P., Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:1 (2010), 2–14.
20. Weber-Dąbrowska, B., Jończyk-Matysiak, E., Żaczek, M., Łobocka, M., Łusiak-Szelachowska, M., Górski, A., Bacteriophage procurement for therapeutic purposes. Front Microbiol, 7, 2016, 1177.
21. Latz, S., Wahida, A., Arif, A., Häfner, H., Hoß M., Ritter, K., et al. Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria. J Basic Microbiol 56:10 (2016), 1117–1123.
22. Mattila, S., Ruotsalainen, P., Jalasvuori, M., On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front Microbiol, 6, 2015, 1271.
23. Azeredo, J., Sillankorva, S., (eds.) Bacteriophage Therapy: From Lab to Clinical Practice [Internet], 2018 [cited 2018 Mar 2]. (Methods in Molecular Biology)Available from: // www.springer.com/la/book/9781493973941.
24. Goodridge, L.D., Designing Phage Therapeutics [Internet]. Current Pharmaceutical Biotechnology, 2009 [cited 2018 Apr 15]. Available from: http://www.eurekaselect.com/71081/article.
25. Chan, B.K., Abedon, S.T., Loc-Carrillo, C., Phage cocktails and the future of phage therapy. Future Microbiol 8:6 (2013), 769–783.
26. Pirnay, J-P, Merabishvili, M., Van Raemdonck, H., De Vos, D., Verbeken, G., Bacteriophage production in compliance with regulatory requirements. Methods Mol Biol Clifton NJ 1693 (2018), 233–252.
27. Malik, D.J., Sokolov, I.J., Vinner, G.K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G.T., et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci 249 (2017), 100–133.
28. Abedon, S.T., Thomas-Abedon, C., Phage therapy pharmacology. Curr Pharm Biotechnol 11:1 (2010), 28–47.
29. Abedon, S.T., Phage therapy: various perspectives on how to improve the art. Methods Mol Biol Clifton NJ 1734 (2018), 113–127.
30. Pirnay, J-P, Blasdel, B.G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J.R., et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res 32 (2015), 2173–2179.
31. Henein, A., What are the limitations on the wider therapeutic use of phage?. Bacteriophage, 3(2), 2013, e24872.
32. Abedon, S.T., Bacteriophage clinical use as antibacterial “drugs”: utility and precedent. Microbiol Spectr, 5(4), 2017.
33. Loc-Carrillo, C., Abedon, S.T., Pros and cons of phage therapy. Bacteriophage 1:2 (2011), 111–114.
34. Vandenheuvel, D., Lavigne, R., Brüssow, H., Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu Rev Virol 2:1 (2015), 599–618.
35. Speck, P., Smithyman, A., Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett, 363(3), 2016.
36. Roach, D., Debarbieux, L., Phage therapy: awakening a sleeping giant. Emerg Top Life Sci 1 (2017), 93–103.
37. Łusiak-Szelachowska, M., Zaczek, M., Weber-Dąbrowska, B., Międzybrodzki, R., Kłak, M., Fortuna, W., et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol 27:6 (2014), 295–304.
38. Żaczek, M., Łusiak-Szelachowska, M., Jończyk-Matysiak, E., Weber-Dąbrowska, B., Międzybrodzki, R., Owczarek, B., et al. Antibody production in response to Staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front Microbiol, 7, 2016, 1681.
39. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., Lecion, D., et al. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep, 5, 2015, 14802.
40. Weber-Dabrowska, B., Zimecki, M., Mulczyk, M., Górski, A., Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol Med Microbiol 34:2 (2002), 135–138.
41. Jończyk-Matysiak, E., Łusiak-Szelachowska, M., Kłak, M., Bubak, B., Międzybrodzki, R., Weber-Dąbrowska, B., et al. The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J Immunol Res, 2015, 2015, 482863.
42. Przerwa, A., Zimecki, M., Switała-Jeleń K., Dabrowska, K., Krawczyk, E., Łuczak, M., et al. Effects of bacteriophages on free radical production and phagocytic functions. Med Microbiol Immunol (Berl) 195:3 (2006), 143–150.
43. WHO | WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. WHO. [cited 2018 Apr 16]. Available from: http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/.
44. Esposito, S., De Simone, G., Update on the main MDR pathogens: prevalence and treatment options. Infez Med Riv Period Eziologia Epidemiol Diagn Clin E Ter Delle Patol Infett 25:4 (2017), 301–310.
45. Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17:2 (2006), 309–317.
46. Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51:2 (2007), 446–452.
47. Fukuda, K., Ishida, W., Uchiyama, J., Rashel, M., Kato, S., Morita, T., et al. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PloS One, 7(10), 2012, e47742.
48. Pabary, R., Singh, C., Morales, S., Bush, A., Alshafi, K., Bilton, D., et al. Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob Agents Chemother 60:2 (2016), 744–751.
49. Kusradze, I., Karumidze, N., Rigvava, S., Dvalidze, T., Katsitadze, M., Amiranashvili, I., et al. Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7as an antibacterial agent. Front Microbiol, 7, 2016, 1590.
50. Regeimbal, J.M., Jacobs, A.C., Corey, B.W., Henry, M.S., Thompson, M.G., Pavlicek, R.L., et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother 60:10 (2016), 5806–5816.
51. Hua, Y., Luo, T., Yang, Y., Dong, D., Wang, R., Wang, Y., et al. Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice. Front Microbiol, 8, 2017, 2659.
52. Kumari, S., Harjai, K., Chhibber, S., Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol 60:Pt 2 (2011), 205–210.
53. Hung, C-H, Kuo, C-F, Wang, C-H, Wu, C-M, Tsao, N., Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 55:4 (2011), 1358–1365.
54. Cao, F., Wang, X., Wang, L., Li, Z., Che, J., Wang, L., et al. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. BioMed Res Int, 2015, 2015, 752930.
55. Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., et al. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med 17:2 (2006), 347–355.
56. Dufour, N., Debarbieux, L., Fromentin, M., Ricard, J-D, Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 43:6 (2015), e190–e198.
57. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B., et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70:1 (2002), 204–210.
58. Cheng, M., Liang, J., Zhang, Y., Hu, L., Gong, P., Cai, R., et al. The Bacteriophage EF-P29 efficiently protects against lethal vancomycin-resistant Enterococcus faecalis and alleviates gut microbiota imbalance in a murine bacteremia model. Front Microbiol, 8, 2017, 837.
59. Wills, Q.F., Kerrigan, C., Soothill, J.S., Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49:3 (2005), 1220–1221.
60. Oduor, J.M.O., Onkoba, N., Maloba, F., Arodi, W.O., Nyachieo, A., Efficacy of lytic Staphylococcus aureus bacteriophage against multidrug-resistant Staphylococcus aureus in mice. J Infect Dev Ctries 10:11 (2016), 1208–1213.
61. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., Iannelli, D., Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51:8 (2007), 2765–2773.
62. Kishor, C., Mishra, R.R., Saraf, S.K., Kumar, M., Srivastav, A.K., Nath, G., Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J Med Res 143:1 (2016), 87–94.
63. Jennes, S., Merabishvili, M., Soentjens, P., Pang, K.W., Rose, T., Keersebilck, E., et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care Lond Engl, 21(1), 2017, 129.
64. Chan, B.K., Turner, P.E., Kim, S., Mojibian, H.R., Elefteriades, J.A., Narayan, D., Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018:1 (2018), 60–66.
65. Kutateladze, M., Adamia, R., Phage therapy experience at the Eliava Institute. Med Mal Infect 38:8 (2008), 426–430.
66. Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., et al. Chapter 3 - Clinical Aspects of Phage Therapy. Łobocka, M, Szybalski, W, (eds.) Advances in Virus Research [Internet], 2012, Academic Press, 73–121 [cited 2018 Mar 5](Bacteriophages, Part B; vol. 83). Available from: http://www.sciencedirect.com/science/article/pii/B9780123944382000037.
67. Fish, R., Kutter, E., Wheat, G., Blasdel, B., Kutateladze, M., Kuhl, S., Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 25:Sup7 (2016), S27–S33.
68. Rhoads, D.D., Wolcott, R.D., Kuskowski, M.A., Wolcott, B.M., Ward, L.S., Sulakvelidze, A., Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:6 (2009), 237–238 240–3.
69. Wright, A., Hawkins, C.H., Anggård, E.E., Harper, D.R., A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol Cervico-Facial Surg 34:4 (2009), 349–357.
70. Sarker, S.A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4 (2016), 124–137.
71. Phagoburn: Evaluation of phage therapy for the treatment of burn wound infections [Internet]. [cited 2018 Apr 22]. Available from: http://www.phagoburn.eu/.
72. Rossitto, M., Fiscarelli, E.V., Rosati, P., Challenges and promises for planning future clinical research into bacteriophage therapy against Pseudomonas aeruginosa in cystic fibrosis. An argumentative review. Front Microbiol, 9, 2018, 775.
73. Nelson, D.C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D.G., Dong, S., et al. Chapter 7 - Endolysins as Antimicrobials. Łobocka, M, Szybalski, W, (eds.) Advances in Virus Research [Internet], 2012, Academic Press, 299–365 [cited 2018 Mar 5](Bacteriophages, Part B; vol. 83). Available from: http://www.sciencedirect.com/science/article/pii/B9780123944382000074.
74. Oliveira, H., São-José C., Azeredo, J., Phage-derived peptidoglycan degrading enzymes: challenges and future prospects for in vivo therapy. Viruses, 29(6), 2018, 10.
75. Pires, D.P., Cleto, S., Sillankorva, S., Azeredo, J., Lu, T.K., Genetically engineered phages: a review of advances over the last decade. Microbiol Mol Biol Rev 80:3 (2016), 523–543.
76. Lu, T.K., Collins, J.J., Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 106:12 (2009), 4629–4634.
77. Edgar, R., Friedman, N., Molshanski-Mor, S., Qimron, U., Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 78:3 (2012), 744–751.
78. Citorik, R.J., Mimee, M., Lu, T.K., Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32:11 (2014), 1141–1145.
79. Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32:11 (2014), 1146–1150.
80. Yosef, I., Manor, M., Kiro, R., Qimron, U., Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A 112:23 (2015 Jun 9), 7267–7272.
81. Viertel, T.M., Ritter, K., Horz, H-P, Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother 69:9 (2014), 2326–2336.
82. Fauconnier, A., Guidelines for bacteriophage product certification. Methods Mol Biol Clifton NJ 1693 (2018), 253–268.